Immune Design Культура компании

Mr. Stephen R. Brady, also known as Steve, LL.M., J.D. has been Executive Vice President of Strategy & Finance at Immune Design Corp since May 2015. Mr. Brady served as the Chief Business Officer at Immune Design Corp. since September 2013. He leads Immune Design's business functions, including strategic planning and corporate development activities. Mr. Brady served as the Chief Business Officer of 3-V Biosciences, Inc. since February 2011. He served as Vice President of Corporate Development, Strategy & Operations at 3-V Biosciences, Inc. from 2010 to February 2011, where he led business and operations activities, including finance, legal, corporate communications and strategic portfolio planning. Mr. Brady was the Executive Director of Corporate Development at Onyx Therapeutics, Inc. since March 2009. He served as an Executive Director of Business & Legal Affairs at Onyx Therapeutics, Inc. from April 2007 to March 2009. From 2001 to 2007, he served as Senior Corporate Counsel of Lexicon Pharmaceuticals Inc., where he served in business development, communications and corporate legal capacities. He served as Vice President of Lazard Venture Advisors, a division of Lazard Freres & Co., LLC and as an Associate in the New York and San Francisco offices of Morrison & Foerster LLP. Mr. Brady holds a BA in English from the University of Oregon, a J.D. from the University of the Pacific and a LLM from the New York University School of Law.

Dr. Sergey Yurasov, M.D., Ph.D., has been Chief Medical Officer and Senior Vice President of Clinical Development at Immune Design Corp. since October 4, 2016. Dr. Yurasov served at Clovis Oncology as Senior Vice President of Clinical Development and oversaw all clinical activities for its rociletinib, rucaparib and lucitanib programs, including regulatory approval and launch support for rociletinib and rucaparib. Dr. Yurasov served as an Associate Vice-President of Global Medicine Science at ImClone Systems, a subsidiary of Eli Lilly & Co. where he led the development of ramucirumab culminating in the FDA submission for second line non-small cell lung cancer indication. He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development. Prior to his industry experience, Dr. Yurasov served as an Assistant Professor of Clinical Investigation at Rockefeller University, where he was the principal investigator for NIH funded translational immunology research and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician. Dr. Yurasov has an extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development, including registration trials and regulatory submissions and reviews. He has an esteemed career as an immunologist and oncologist spans industry, academia and clinical practice and has an invaluable expertise and insight. He is a board-certified, U.S. licensed hematologist/oncologist with more than 20 years of experience in immunology and oncology Dr. Yurasov has a M.D. from the Russian State Medical University and has a Ph.D. in Medical Sciences from the Research Institute for Pediatric Oncology in Moscow, Russia. He thereafter completed his residency in general pediatrics at Albert Einstein College of Medicine/Jacobi Medical Center and has subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center. He was a Research Fellow at The Rockefeller University in Dr. M. Nussenzweig''??s laboratory.

Mr. Christopher Whitmore, also known as Chris, CPA., has been Vice President of Finance and Administration at Immune Design Corp. since May 31, 2015. Mr. Whitmore joined Immune Design from AcelRx Pharmaceuticals, Inc., where he was the Senior Director of Finance and Corporate Controller.

Dr. Frank J. Hsu, M.D. has been the Head of Oncology and Vice President at Immune Design Corp. since October 24, 2013. Dr. Hsu served as the Chief Medical Officer of Zyngenia, Inc. since May 2012, where he was responsible for strategic planning and clinical development of multi-specific, multi-valent agents for the company's lead programs in immune-mediated diseases and oncology. Prior to joining Zyngenia, Dr. Hsu served as Senior Medical Director at Genzyme in the Transplant and Oncology Division. From 1990 to 1996, he was a clinical and research fellow in Oncology at Stanford University. Dr. Hsu joined the faculty of Yale University in 1996 and served as an Assistant Professor of Medicine in the Section of Oncology and as co-Director of the Immunology Research Program of the Yale Cancer Center until 2003. During his academic career, Dr. Hsu's research focused on non-Hodgkin's lymphomas, Hodgkin's disease and multiple myeloma. His work involved both basic immunology and translational efforts to develop novel anti-cancer antibodies and idiotype vaccines for the treatment of B cell non-Hodgkin's lymphomas and included the first clinical trial of an anti-cancer vaccine based on antigen-pulsed dendritic cells. He was a recipient of several awards including the James S. McDonnell Fellow Award for Molecular Medicine in Cancer Research and was a translational research fellow of the Leukemia and Lymphoma Society. Dr. Hsu also serves on the Board of Trustees of the Grunebaum Cancer Research Foundation. Dr. Hsu received his undergraduate degree from Stanford University and his medical degree from Harvard Medical School as part of the Health, Science and Technology (Harvard-MIT) program. His residency training in Internal Medicine was at the University of California, San Francisco.

Mr. James Paul Rickey, CPA served as consultant at Immune Design Corp. since June 2015 until February 2016. Mr. Rickey served as Vice President of Finance & Administration, Treasurer and Secretary at Immune Design Corp. from July 2009 to May 31, 2015. He served as Director of Finance at Immune Design Corp. since July 2009. Mr. Rickey served as Corporate Controller, at Northstar Neuroscience from 2006 to 2009. He served as the Accounting Manager at Mobliss, a wireless software company, from 2004 to 2006 and was an employee of Ernst & Young LLP from 2001 to 2004. He serves on the Board of the Northwest Association of Bioscience Financial Officers and received his Certified Public Accountant Certification from the State of Washington and holds an active license. Mr. Rickey received a B.A. in Business Administration & Accounting, and a Master in Professional Accounting from the University of Washington.

Dr. Wayne R. Gombotz, Ph.D. has been the Chief Development Officer of Immune Design Corp. since December 2, 2011. Dr. Gombotz oversees product development and manufacturing for Immune Design's therapeutic vaccine product candidates. He has 20 years of experience providing technical and administrative direction of clinical and commercial manufacturing operations, process development and process validation functions. He served as a Vice President of Pharmaceutical Operations at Omeros Corporation since March 2005. He served as Vice President of Pharmaceutical Operations at Omeros Medical Systems Inc. since April 2005. He was responsible for product development and manufacturing for Omeros' pharmaceutical and biopharmaceutical technology platforms. He served as Vice President of Process Science and Pharmaceutical Development for GSK Biologicals Seattle from 2002 to 2005. He served as Senior Director of Analytical Chemistry and Formulation at Amgen from 1995 to 2002, where he was responsible for analytical characterization, method development, formulation, drug delivery and in-process testing. Dr. Gombotz served as a Senior Research Investigator for Bristol-Myers Squibb. He served as a Research Scientist and Project Leader of Enzytech. He serves as an Editorial Advisory Board Member of the publications Pharmaceutical Technology and European J. of Pharmaceutics and Biopharmaceutics. He serves as an Editorial Advisory Board Member of the publication Pharmaceutical Technology. He serves as an Advisory Board Member at University of Washington's Microscale Life Science Center and the Washington Center for Advanced Materials Technology. He is an affiliate faculty member of the University of Washington and earned his MS and Ph.D. in Bioengineering. Dr. Gombotz also holds a BA in biology from Colby College.

Sergey Yurasov serves as the Senior Vice President, Chief Medical Officer of Immune Design. Sergey started at Immune Design in Oct of 2016. Sergey currently resides in the San Francisco Bay Area.

Heidi Petersen serves as the Vice President of Immune Design. Heidi started at Immune Design in Jun of 2017. Heidi currently resides in the San Francisco Bay Area.

Fred Kerwood serves as the Vice President of Clinical Operations & Project Management of Immune Design. Fred started at Immune Design in August of 2018. Fred currently resides in the San Francisco Bay Area.